Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Restoration Biologics
Deal Size : $61.0 million
Deal Type : Licensing Agreement
Enveric, Restoration Bio Sign Licensing Deals for Joint Disease Treatments
Details : Under the licensing agreement, Restoration will gain the rights of cannabinoid-COX-2 conjugate compounds. It is being used for the joint pathology, such as osteoarthritis and rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 04, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Restoration Biologics
Deal Size : $61.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac hydrogel patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Details : Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in a...
Product Name : DLP-208
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 16, 2021
Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Implant Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details :
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 28, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Implant Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Autologous Adipose-Derived Regenerative Cell
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study reveals favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 04, 2020
Lead Product(s) : Autologous Adipose-Derived Regenerative Cell
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid,Type II Collagen
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Bioiberica
Deal Size : Undisclosed
Deal Type : Partnership
Details : Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Product Name : Meritene Mobilis
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Hyaluronic Acid,Type II Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Bioiberica
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Chondrocytes
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Biosolution
Deal Size : Undisclosed
Deal Type : Agreement
Mundipharma, Biosolution to market CartiLife in South Korea
Details : Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Chondrocytes
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Biosolution
Deal Size : Undisclosed
Deal Type : Agreement